论文部分内容阅读
目的:分析宫腔内灌注人绒毛膜促性腺激素(HCG)对冻融胚胎移植周期反复着床失败(RIF)妊娠结局的影响。方法:选定郑州大学第二附属医院2018年5月至2020年5月住院治疗的120例胚胎RIF再次接受冻融胚胎移植(FET)治疗的患者，依据治疗方案分组(每组病例数共计60例)，参照组采用宫腔内灌注生理氯化钠溶液治疗，观察组采用宫腔内灌注HCG治疗，比较两组子宫内膜指标、子宫内膜血流类型、临床妊娠率、生化妊娠率、胚胎种植率。结果:观察组治疗4周后子宫内膜厚度、搏动指数(PI)均高于参照组，观察组治疗4周后阻力指数(RI)低于参照组，观察组II型＋III型率(78.33%)、临床妊娠率(50.00%)、生化妊娠率(43.33%)、胚胎种植率(30.00%)均高于参照组(21.67%、30.00%、25.00%、13.33%)，观察组I型率(35.00%)低于参照组(65.00%)，差异均有统计学意义(n P<0.05)。n 结论:宫腔内灌注HCG可有效改善胚胎RIF再次接受FET患者子宫内膜血流类型和厚度，提高妊娠率、胚胎种植率。“,”Objective:To analyze the effect of intrauterine infusion of human chorionic gonadotropin (HCG) on the pregnancy outcome of repeated implantation failure (RIF) during the freeze-thaw embryo transfer cycle.Methods:A total of 120 cases of embryonic RIF in the Second Affiliated Hospital of Zhengzhou University from May 2018 to May 2020 who received freeze-thaw embryo transfer (FET) again were selected, and they were grouped by treatment-plan (the number of cases in each group was 60 cases in total), the reference group was treated with intrauterine infusion of physiological saline, and the observation group was treated with intrauterine infusion of HCG. The endometrial indicators, endometrial blood flow types, clinical pregnancy rate, biochemical pregnancy rate, and embryo implantation rate were compared between the two groups.Results:The endometrial thickness and pulsatility index (PI) of the observation group were higher than the reference group after 4 weeks of treatment. The resistance index (RI) of the observation group was lower than that of the reference group after 4 weeks of treatment. The rate of type II + type III (78.33%) and the clinical pregnancy rate (50.00%), biochemical pregnancy rate (43.33%), embryo implantation rate (30.00%) of the observation group were higher than those of the reference group (21.67%, 30.00%, 25.00%, 13.33%), the type I rate of observation group (35.00%) was lower than that of the reference group (65.00%), the differences were statistically significant (n P<0.05).n Conclusions:Intrauterine perfusion of HCG can effectively improve the type and thickness of endometrial blood flow in patients with embryonic RIF receiving FET again, and increase the pregnancy rate and embryo implantation rate.